Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2011Inflammatory Bowel DiseasesOpen Access

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

View Full Paper
Ask AI
Bookmark
Share

Authors

APAsit ParikhJohns Hopkins UniversityTLTimothy LeachForest InstituteTWTim WyantUniversity of Arizona

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Parikh et al. (2011) studied this question.

synapsesocial.com/papers/6a124829bb918b6e5b66fe2dhttps://doi.org/10.1002/ibd.21896
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab2009 · 211 citations
  2. 2Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein2009 · 379 citations
  3. 3Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis2008 · 984 citations
  4. 4A New Fecal Calprotectin Test for Colorectal Neoplasia: Clinical Results and Comparison with Previous Method2001 · 66 citations